 Guardant Health Inc NASDAQ: GH reported Q3 sales of 94.8 million, 27 YY, beating the Wall Street estimate of 92.64 million. Guardants Q3 precision oncology revenues grew 31 to 79.3 million, driven by a 27 increase in clinical testing revenue. 